Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome.

Rodríguez-Ortega MJ, Norais N, Bensi G, Liberatori S, Capo S, Mora M, Scarselli M, Doro F, Ferrari G, Garaguso I, Maggi T, Neumann A, Covre A, Telford JL, Grandi G.

Nat Biotechnol. 2006 Feb;24(2):191-7. Epub 2006 Jan 15.

PMID:
16415855
2.

The next chapter in reverse vaccinology.

Musser JM.

Nat Biotechnol. 2006 Feb;24(2):157-8. No abstract available.

PMID:
16465156
3.

Identification and assessment of new vaccine candidates for group A streptococcal infections.

McMillan DJ, Batzloff MR, Browning CL, Davies MR, Good MF, Sriprakash KS, Janulczyk R, Rasmussen M.

Vaccine. 2004 Jul 29;22(21-22):2783-90.

PMID:
15246612
4.

New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population.

Brandt ER, Sriprakash KS, Hobb RI, Hayman WA, Zeng W, Batzloff MR, Jackson DC, Good MF.

Nat Med. 2000 Apr;6(4):455-9.

PMID:
10742155
5.

Lipid core peptide technology and group A streptococcal vaccine delivery.

Olive C, Batzloff MR, Toth I.

Expert Rev Vaccines. 2004 Feb;3(1):43-58. Review.

PMID:
14761243
6.
7.

Cross-protection between group A and group B streptococci due to cross-reacting surface proteins.

Stâlhammar-Carlemalm M, Areschoug T, Larsson C, Lindahl G.

J Infect Dis. 2000 Jul;182(1):142-9. Epub 2000 Jun 30.

PMID:
10882591
8.

Identification of vaccine candidate antigens of Staphylococcus aureus by serological proteome analysis.

Vytvytska O, Nagy E, Blüggel M, Meyer HE, Kurzbauer R, Huber LA, Klade CS.

Proteomics. 2002 May;2(5):580-90.

PMID:
11987132
9.

Vaccine strategies to prevent rheumatic fever.

Brandt ER, Good MF.

Immunol Res. 1999;19(1):89-103.

PMID:
10374697
10.
11.

Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.

Olive C, Sun HK, Ho MF, Dyer J, Horváth A, Toth I, Good MF.

J Infect Dis. 2006 Aug 1;194(3):316-24. Epub 2006 Jun 30.

PMID:
16826479
12.

Application of genomics and proteomics for identification of bacterial gene products as potential vaccine candidates.

Chakravarti DN, Fiske MJ, Fletcher LD, Zagursky RJ.

Vaccine. 2000 Nov 8;19(6):601-12.

PMID:
11090710
13.

Identification and characterization of a novel heme-associated cell surface protein made by Streptococcus pyogenes.

Lei B, Smoot LM, Menning HM, Voyich JM, Kala SV, Deleo FR, Reid SD, Musser JM.

Infect Immun. 2002 Aug;70(8):4494-500.

14.

Surfome analysis as a fast track to vaccine discovery: identification of a novel protective antigen for Group B Streptococcus hypervirulent strain COH1.

Doro F, Liberatori S, Rodríguez-Ortega MJ, Rinaudo CD, Rosini R, Mora M, Scarselli M, Altindis E, D'Aurizio R, Stella M, Margarit I, Maione D, Telford JL, Norais N, Grandi G.

Mol Cell Proteomics. 2009 Jul;8(7):1728-37. doi: 10.1074/mcp.M800486-MCP200. Epub 2009 Apr 28.

15.

Prospecting for new group A streptococcal vaccine candidates.

McMillan DJ, Davies MR, Browning CL, Good MF, Sriprakash KS.

Indian J Med Res. 2004 May;119 Suppl:121-5.

PMID:
15232176
16.

Synthesis and in vivo studies of carbohydrate-based vaccines against group A streptococcus.

Simerska P, Abdel-Aal AB, Fujita Y, Batzloff MR, Good MF, Toth I.

Biopolymers. 2008;90(5):611-6. doi: 10.1002/bip.20992.

PMID:
18381625
17.

Multi high-throughput approach for highly selective identification of vaccine candidates: the Group A Streptococcus case.

Bensi G, Mora M, Tuscano G, Biagini M, Chiarot E, Bombaci M, Capo S, Falugi F, Manetti AG, Donato P, Swennen E, Gallotta M, Garibaldi M, Pinto V, Chiappini N, Musser JM, Janulczyk R, Mariani M, Scarselli M, Telford JL, Grifantini R, Norais N, Margarit I, Grandi G.

Mol Cell Proteomics. 2012 Jun;11(6):M111.015693. doi: 10.1074/mcp.M111.015693. Epub 2012 Jan 27.

18.

Prospects for a group A streptococcal vaccine.

McMillan DJ, Chhatwal GS.

Curr Opin Mol Ther. 2005 Feb;7(1):11-6. Review.

PMID:
15732524
19.

Nonimmunodominant regions are effective as building blocks in a streptococcal fusion protein vaccine.

Stålhammar-Carlemalm M, Waldemarsson J, Johnsson E, Areschoug T, Lindahl G.

Cell Host Microbe. 2007 Dec 13;2(6):427-34.

Supplemental Content

Support Center